CPG
SUPN icon

Cornerstone Planning Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Cornerstone Planning Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15
Closed -$591 – 1678
2024
Q4 		$591 Buy
+15
New +$528 ﹤0.01% 1082

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Cornerstone Planning Group's SUPN Position: Q1 2025 in Review

Cornerstone Planning Group sold out of Supernus Pharmaceuticals (SUPN) in Q1 2025, closing a stake of 15 shares — an estimated $591 sold.

Cornerstone Planning Group first reported a position in SUPN in Q4 2024 and held it in 1 quarter. The position peaked at $591 in Q4 2024. 295 funds tracked by Wall St. Rank hold SUPN as of Q1 2025.

  • Cornerstone Planning Group reported no remaining Supernus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Cornerstone Planning Group sold 15 Supernus Pharmaceuticals shares in Q1 2025, an estimated $591.
  • Cornerstone Planning Group first reported a position in Supernus Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Cornerstone Planning Group's Supernus Pharmaceuticals position peaked at $591 in Q4 2024.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2025.

Based on Cornerstone Planning Group's 13F filing for Q1 2025, filed 30 Apr 2025.